Immunopotentiating Reconstituted Influenza Virosomes (IRIVs)

  • Reinhard Glück
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 42)


Immunization is the most effective defense mechanism against microbial infections today. Although highly effective vaccines are currently available for a number of infectious diseases, vaccine formulations can still be improved in a number of important areas. Issues of safety, stability, delivery, and combining vaccines to several pathogens need to be addressed. For many diseases, a greater understanding of microbial pathogenesis and the basis for protective immunity is still needed. The ability to induce antigen-specific humoral and cell-mediated immunity is crucial to the development of effective prophylactic and therapeutic vaccines.


Influenza Virus Influenza Vaccine Tetanus Toxoid Diphtheria Toxoid Mumps Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Gould-Fogerite, S. and Mannino, R. J. (1996) Mucosal and systemic immuniza-tion using cochleate and liposome vaccines. J. Liposom. Res. 6, 357–379.CrossRefGoogle Scholar
  2. 2.
    Garçon, N. and Friede, M. (1996) Liposomes to induce potent humoral responses to T-independent antigens. J. Liposom. Res. 6, 381–395.CrossRefGoogle Scholar
  3. 3.
    Morein, B. and Simons, K. (1985) Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. Vaccine 3, 83–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Muller, G. M., Shapira, M., and Arnon, R. (1982) Anti-influenza response achieved by immunization with a synthetic conjugate. Proc. Natl. Acad. Sci. USA 79, 569–573.PubMedCrossRefGoogle Scholar
  5. 5.
    Boudreault, A. and Thibodeau, L. (1985) Mouse response to influenza immu-nosomes. Vaccine 3, 231–234.PubMedCrossRefGoogle Scholar
  6. 6.
    Neurath, A. R., Kent, S. B. H., and Strick, N. (1984) Antibodies to hepatitis B surface antigen (HBsAG) elicited by immunization with a synthetic pep tide covalently linked to liposomes. J. Gen. Virol. 65, 1009–1014.PubMedCrossRefGoogle Scholar
  7. 7.
    Lerner, R. A., Green, N., Alexander, H., Liu, F.-T., Sutcliffe, J. G., and Shinnick, T. M. (1981) Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles. Proc. Natl. Acad. Sci. USA 78, 3403–4307.PubMedCrossRefGoogle Scholar
  8. 8.
    Bhatnagar, P. K., Papas, E., Blum, H. E., Milich, D. R., Nitecki, D., Karels, M. J., and Vyas, G. N. (1982) Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the A determinant. Proc. Natl. Acad. Sci. USA 79, 4400–4404.PubMedCrossRefGoogle Scholar
  9. 9.
    Bittle, J. L., Houghton, R. A., Alexander, H., Shinnik, T. M., Sutcliffe, J. G., Lerner, R. A., et al. (1982) Protection against foot and mouth disease by immunization with a chemically synthesized peptide predicted form the viral nucleotide sequence. Nature 298, 30–33.PubMedCrossRefGoogle Scholar
  10. 10.
    DiMarchi, R., Brooke, G., Gale, C., Cracknell, V., Doel, T., and Mowat, N. (1986) Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 232, 639–641.PubMedCrossRefGoogle Scholar
  11. 11.
    Kennedy, R. C., Henkel, R. D., Pauletti, D., Allan, J. S., Lee, T. H., Essex, M., and Dressman, G. R. (1986) Antiserum to a synthetic peptide recognizes the HTLVIII envelope glycoprotein. Science 231, 1556–1559.PubMedCrossRefGoogle Scholar
  12. 12.
    Miller, L. H., Howard, R. D., Carter, R., Good, M. D., Nussenzweig, V., and Nussenzweig, R. S. (1986) Research toward malaria vaccines. Science 234, 1349–1356.PubMedCrossRefGoogle Scholar
  13. 13.
    Caryanniotis, G. and Barber, B. H. (1987) Adjuvant-free IgG responses induced with antigen coupled to antibodies against class IIMHC. Nature 327, 59–61.CrossRefGoogle Scholar
  14. 14.
    Francis, M. J., Fry, C. M., Rowlands, D. J., Brown, F., Bittle, J. L., Houghten, R. A., and Lerner, R. A. (1985) Immunological priming with synthetic peptides of foot-and-mouth disease virus. J. Gen. Virol. 66, 2347–2354.PubMedCrossRefGoogle Scholar
  15. 15.
    Goodman-Snitkoff, G., Eisele, L. E., Heimer, E. P., Felix, A. M., Andersen, T. T., Fuerst, T. R., and Mannino, R. J. (1990) Defining minimal requirements for antibody production to peptide antigens. Vaccine 8, 257–262.PubMedCrossRefGoogle Scholar
  16. 16.
    Goodman-Snitkoff, G., Good, M. R., Berzofsky, J. A., and Mannino, R. J. (1991) Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes. J. Immunol. 147, 410–415.PubMedGoogle Scholar
  17. 17.
    Mannino, R. J. and Gould-Fogerite, S. (1995) Lipid matrix-based vaccines for mucosal and systemic immunization, in Vaccine Design: The Subunit and Adjuvant Approach (Powell, M. F. and Newman, M. J., eds.), Plenum, New York, p. 363.Google Scholar
  18. 18.
    Allen, P. M. (1987) Antigen processing at the molecular level. Immunol. Today 8, 270–273.CrossRefGoogle Scholar
  19. 19.
    Gould-Fogerite, S. and Mannino, R. J. (1985) Rotary dialysis: Its application to the production of large liposomes and large proteoliposomes (protein-lipid vesicles) with high encapsulation efficiency and efficient reconstitution of membrane proteins. Anal. Biochem. 148, 15.PubMedCrossRefGoogle Scholar
  20. 20.
    Gould-Fogerite, S., Mazurkiewicz, J., Lehman, J., Raska, Jr., K., Voelkerding, K., and Mannino, R. J. (1989) Chimerasome-mediated gene transfer in vitro and in vivo. Gene 84, 429–438.PubMedCrossRefGoogle Scholar
  21. 21.
    Gould-Fogerite, S., Mazurkiewicz, J. E., Bhisitkul, D., and Mannino, R. J. (1987) The reconstitution of biologically active glycoproteins into large liposomes: Use as a delivery vehicle to animal cells, in Advances in Membrane Biochemistry and Bioenergetics (Kim, C. H., Diwan, J., Tedeschi, H., and Salerno, J. J., eds.), Plenum, New York, pp. 569–591.Google Scholar
  22. 22.
    Mannino, R. J. and Gould-Fogerite, S. (1988) Liposome mediated gene transfer. Biotechniques 6, 682–690.PubMedGoogle Scholar
  23. 23.
    Miller, M. D., Gould-Fogerite, S., Shen, L., Woods, R. M., Koenig, S., Mannino, R. J., and Letvin, N. L. (1992) Vaccination of rhesus monkeys with synthetic peptide in a fusogenic proteoliposome elicits simian immunodeficiency virus-specific CD8+cytotoxic T lymphocytes. J. Exp. Med. 176, 1739–1744.PubMedCrossRefGoogle Scholar
  24. 24.
    Gould-Fogerite, S., Edghill-Smith, Y., Kheiri, M., Wang, Z., Das, K., Feketeova, E., et al. (1994) Lipid matrix-based subunit vaccines: A structure-function approach to oral and parenteral immunization. AIDS Res. Hum. Retrovirus. 10, 99.Google Scholar
  25. 25.
    Allison, A. C. and Gregoriadis, G. (1974) Liposomes as immunological adjuvants. Nature 252, 252–255.PubMedCrossRefGoogle Scholar
  26. 26.
    Gregoriadis, G. (1990) Immunological adjuvants: a role for liposomes. Immunol. Today 11, 89–97.PubMedCrossRefGoogle Scholar
  27. 27.
    Glück, R. (1994) Combined vaccines-the european contribution. Biologicals 22, 347–351.PubMedCrossRefGoogle Scholar
  28. 28.
    Glück, R., Mischler, R., Brantschen, S., Just, M., Althaus, B., and Cryz, S. J. Jr. (1992) Immunopotentiating reconstituted influenza virosome (IRIV) vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90, 2491–2495.PubMedCrossRefGoogle Scholar
  29. 29.
    Gregoriadis, G. (1995) Engineering liposomes for drug delivery: progress and problems. TIBTECH 13, 527–537.Google Scholar
  30. 30.
    Seganti, L., Superti, F., Orsini, N., Gabrielli, R., Divizia M., and Panà, A. (1989) Membrane lipid components interacting with hepatitis A virus. Microbiologica 12, 225–230.PubMedGoogle Scholar
  31. 31.
    Garçon, N. M. and Six, H. R. (1991) Universal Vaccine Carrier. Liposomes that provide T-dependent help to weak antigen. J. Immunol. 146/11, 3697–3702.Google Scholar
  32. 32.
    Tsurudome, M., Glück, R., Graf, R., Falchetto, R., Schaller, U., and Brunner, J. (1992) Lipid interactions of the hemagglutinin HA2NH2-terminal segment during influenza virus-induced membrane fusion. J. Biol. Chemistry 267/28, 20,225–20,232.Google Scholar
  33. 33.
    Durrer, P., Galli, C., Hoenke, S., Corti, C., Glück, R., Vorherr, T., and Brunner, J. (1996) H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. 271/23, 13,417–13,421.Google Scholar
  34. 34.
    Matlin, K. S., Reggio, H., Helenius, A., and Simmons, K. (1981) Infections entry pathway of influenza virus in a canine kidney cell line. J. Cell. Biol. 91, 601–613.PubMedCrossRefGoogle Scholar
  35. 35.
    Rott, O., Charreire, J., Mignon-Godefroy, K., and Cash, E. (1995) B cell super-stimulatory influenza virus activates peritoneal B cells. J. Immunology 155, 134–142.Google Scholar
  36. 36.
    Rott, O., Charreire, J., Semichon, M., Bismuth, G., and Cash, E. (1995) B cell superstimulatory influenza virus (H2-subtype) induces B cell proliferation by a PKC-activating, Ca2+-Independent mechansim. J. Immunology 154, 2092–2103.Google Scholar
  37. 37.
    Parker, E. E. and Gould, K. G. (1996) Influenza A virus-a model for viral antigen presentation to cytotoxic T lymphocytes. Virology 7, 61–73.Google Scholar
  38. 38.
    Air, G. M. and Laver, W. G. (1989) The neuraminidase of influenza virus. Proteins 6, 341–356.PubMedCrossRefGoogle Scholar
  39. 39.
    Muster, T., Ferko, B., Klima, A., Purtscher, M., Trkola, A., Schulz, P., et al. (1995) Mucosal model of immunization against human immunodeficiency virus Type 1 with a chimeric influenza virus. J. Virology 69/11, 6678–6686.Google Scholar
  40. 40.
    Mengiardi, B., Berger, R., Just, M., and Glück, R. (1995) Virosomes as carriers for combined vaccines. Vaccine 13, 1306–1315.PubMedCrossRefGoogle Scholar
  41. 41.
    Glück, R. (1993) Towards a universal IRIV traveller vaccine. Third Conference on International Travel Medicine, Paris, France, 25–29, April 1993. Abstr. No. 259.Google Scholar
  42. 42.
    Just, M. (1993) Experience with IRIV as carrier for hepatitis A and other antigens. Third Conference on International Travel Medicine, Paris, France, 25–29, April 1993, Abstr. No. 277.Google Scholar
  43. 43.
    Lea, A. P. and Balfour, J. A. (1997) Virosomal hepatitis A vaccine (strain RG-SB): a preliminary review of its immunogenicity protective efficacy and tolerability in at-risk populations. BioDrugs 7, 232–248.PubMedCrossRefGoogle Scholar
  44. 44.
    Bovier, P., Loutan, L., Farinelly, T., et. al. (1995) Cross-immunogenicity of a booster dose of a virosomal hepatitis A vaccine in healthy travellers after basic immunization with an alum-based hepatitis A vaccine (Abstract). European Conference on Tropical Medicine. Oct. 22-25; Hamburg, Germany.Google Scholar
  45. 45.
    Holzer, B. R., Hatz, C., Schmidt-Sissolak, D., Glück, R., Althaus, B., and Egger, M. (1996) Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14/10, 982–986.CrossRefGoogle Scholar
  46. 46.
    Poovorawan, Y., Theamboonlers, A., Chumdermpadetsuk, S., Glück, R., and Cryz, S. J., Jr. (1995) Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 13/10, 891–893.CrossRefGoogle Scholar
  47. 47.
    Poovorawan, Y., Tieamboonlers, A., Chumdermpadetsuk, S., Glück, R., and Cryz, S. J. (1994) Control of a hepatitis A outbreak by active immunization of high-risk susceptibles subjects. J. Infect. Dis. 169, 228–229 (Letter to the Editor).PubMedCrossRefGoogle Scholar
  48. 48.
    Glück, R., Mischler, R., Finkel, B., Que, J. U., Scarpa, B., and Cryz, S. J., Jr. (1994) Immunogenicity of new virosome influenza vaccine in the elderly people. Lancet 344, 160–163.PubMedCrossRefGoogle Scholar
  49. 49.
    Conne, P., Gauthey, L., Vernet, P., Althaus, B., Que, J. U., Finkel, B., et al. (1997) Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15/15, 1675–1679.CrossRefGoogle Scholar
  50. 50.
    Glück, U., Gebbers, J. O., and Glück, R. (1998) Intranasal application of virosome influenza vaccine. Submitted (Lancet).Google Scholar
  51. 51.
    Zurbriggen, R. and Glück, R. (1998) Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine, in press.Google Scholar
  52. 52.
    Pöltl-Frank, F., Zurbriggen, R., Helg, aStuart, F., Robinson, J., Glück, R., and Pluschke, G. Use of reconstituted influenza virus virosomes as an immuno-potentiating delivery system for a peptide-based vaccine. In press.Google Scholar
  53. 53.
    Wälti, E. R. and Glück, R. (1998) Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer 77, 728–733.Google Scholar
  54. 54.
    Lowell, G. H. (1990) Proteosomes, hydrophobic anchors, iscoms and liposomes for improved presentation of peptide and protein vaccines, in New Generation Vaccines (Woodrow, G. C. and Levine, M. M., eds.), Dekker, New York, pp.141–168.Google Scholar
  55. 55.
    Cusi, M. G. and Glück, R. (1998) Intranasal immunization of mice with mumps DNA entrapped into influenza virosomes. IBC’s 4th Ann. Conf. Genet. Vacc., Oct. 25-27, Washington, D.C.Google Scholar
  56. 56.
    Eng, R. S., Pomerantz, R. J., and Friedman, L. S. (1993) Hepatitis A vaccines: past, present and future. Gastroenterology 105, 943–945.PubMedGoogle Scholar
  57. 57.
    Cryz, S., Que, J. U., and Glück, R. (1996) A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine 14, 1381–1383.PubMedCrossRefGoogle Scholar
  58. 58.
    The European Agency for the Evaluation of Medicinal Products (EMA), Human Medicines Evaluation Unit: Committee for Proprietary Medicinal Products (CPMP), in Note for Guidance on Harmonisation of Requirements for Influenza Vaccines; 12 March 1997 (CPMP/BWP/214/96).Google Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Reinhard Glück
    • 1
  1. 1.Head, Virology, Swiss Serum and Vaccine Institute BerneBerneSwitzerland

Personalised recommendations